Author

Jonathan Chernoff

Primary ORCID profile (0000-0002-4803-7836 · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Jonathan ChernoffiD3 papers · Fox Chase Cancer Center

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Alexa C. Cannon· 1 shared Alison M. Kurimchak· 1 shared Cristina Uribe-Alvarez· 1 shared Daniela Araiza-Olivera· 1 shared James S. Duncan· 1 shared Kathy Q. Cai· 1 shared Konstantin Budagyan· 1 shared Suraj Peri· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexa C. Cannon

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintJun 27, 2023

Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints

Alexa C. Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez…·Jonathan Chernoff

This study identifies CDK9 as a novel therapeutic target in RAC1P29S-mutant melanoma and shows that combining CDK9 inhibition with anti-PD-1 therapy enhances tumor suppression.

DOI 10.1101/2023.06.27.546707

humanbulk RNA-seq

𝕏 PostBluesky